



## Cytokinetics to Present at March Healthcare Conferences

February 22, 2011 9:00 PM EST

SOUTH SAN FRANCISCO, CA, Feb 22, 2011 (MARKETWIRE via COMTEX) --

Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the following healthcare conferences during the month of March:

2011 Citi Global Healthcare Conference Date: Tuesday, March 1, 2011

Time: 11:30a.m. Eastern Time Location: New York Hilton Hotel, New York, New York

Credit Suisse One-on-One Healthcare Conference Date: Thursday, March 3, 2011 Location: Credit Suisse Offices, Canary Wharf, London

Cowen & Company 31st Annual Health Care Conference Date: Monday, March 7, 2011 Time: 3:15p.m. Eastern Time Location: Boston Marriott Copley Place Hotel, Boston, Massachusetts

Roth Capital Partners 23rd Annual OC Growth Conference Date: Monday, March 14, 2011 Time: 10:00a.m. Pacific Time Location: Ritz Carlton Laguna Niguel, Dana Point, California

Interested parties may access the live audio webcasts of the Citi, Cowen and Roth presentations by visiting the Investor Relations section of the Cytokinetics website at [www.cytokinetics.com](http://www.cytokinetics.com). The webcast replay of these three presentations will be archived on the Presentations page within the Investor Relations section of Cytokinetics' website for two weeks following the completion of the event.

### About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil (formerly CK-1827452), is in clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. CK-2017357 is currently the subject of a Phase IIa clinical trials program and has been granted orphan-drug designation by the U.S. Food and Drug Administration for the potential treatment of amyotrophic lateral sclerosis. Cytokinetics is also conducting non-clinical development of compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions associated with excessive smooth muscle contraction, such as bronchoconstriction associated with asthma and chronic pulmonary obstructive disease. In addition, prior Cytokinetics' research generated three anti-cancer drug candidates that have progressed into clinical development: ispinesib, SB-743921 and GSK-923295. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at [www.cytokinetics.com](http://www.cytokinetics.com).

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations, and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

### Contacts:

Cytokinetics, Incorporated  
Christopher S. Keenan (Investors and Media)  
Director, Investor Relations  
(650) 624-3000

SOURCE: Cytokinetics, Inc.